#For patients
Written for adults considering a peptide as part of their health management.
How semaglutide works across the body
A 2026 review reads semaglutide through a systems medicine lens, tracing the GLP-1 receptor agonist from trial outcomes to the molecular mediators underneath.
Eating disorder screens predict GLP-1 use
A US survey of 1,309 adults links positive eating disorder screens to higher GLP-1 awareness and telehealth drug-seeking.
BPC-157 oral vs injectable for gut health
No human trial has compared oral BPC-157 tablets to reconstituted injectable for gut health. Here is what rodent data and the supply chain show.
BPC-157 personal reviews: what they show
Personal peptide reviews name doses and outcomes but lack controls and verified purity. Here is how to read them against actual BPC-157 data.
What is BPC-157? A plain-English explainer
BPC-157 is a synthetic peptide from human gastric juice studied in rodents for tissue repair. No controlled human trial exists, and it is not approved anywhere.
Boerhaave syndrome after semaglutide use
A 2026 case report describes the first documented esophageal perforation linked to GLP-1 agonist-induced vomiting after skipping dose titration.
Dupuytren's contracture and peptides
Dupuytren's contracture surfaces in peptide forums alongside GLP-1 drugs. The biological overlap with fibrotic pathways is real. The direct evidence is not.
Microdosing tirzepatide: what we know
No trial has tested tirzepatide below 2.5 mg. A 2026 Obesity commentary examines the growing practice of KwikPen microdosing.
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
Semaglutide and menstrual changes
Semaglutide users report heavier periods and cycle shifts. Here is what safety data and clinical research say about GLP-1 agonists and menstruation.
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
GLP-1 constipation: prevalence vs incidence
A 2026 study argues many GLP-1 users had constipation before starting treatment, inflating the headline rate.